IPO Timeline
Broker Results (T-2)
2020-07-06
Some brokers release in afternoon
Grey Market (T-1)
2020-07-07
Afternoon
HKEX Allotment (T-1)
2020-07-07
Evening
Registrar Allotment (T-1)
2020-07-07
Evening
Listing Day (T)
2020-07-08
First day of trading
Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 海普瑞 |
|---|---|
| Other Market Stock Code | 002399 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 深圳市海普瑞藥業集團股份有限公司 |
|---|---|
| Stock Code | 09989 |
| Company Full Name | 深圳市海普瑞藥業集團股份有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生產及銷售藥品，亦從事創新藥物開發以及提供CDMO服務。 |
| Listing Date | 2020-07-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省深圳市南山區郎山路21號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.hepalink.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 18.40 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 21.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,619,899,200 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 17.66 |
|---|---|
| First Day Open | HK$ 18.46 |
| First Day Change | -4.02% |
| First Day Volume | 103317000.0 |
| First Day Turnover | 1873060000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30.0%或約1,141.7百萬港元，用于改善資本結構及償還現有債務； 2、約30.0%或約1,141.7百萬港元，用于我們在歐盟及其他全球市場（如中國）拓展銷售及營銷網絡以及基礎設施； 3、約20.0%或約761.1百萬港元，用于提升我們的開發及生產能力，并擴大我們向賽灣生物提供的產品及服務； 4、約20.0%或約761.1百萬港元，用于創新藥的投資。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
Joint Bookrunners (8)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
海通国际证券有限公司 CE AAF806
中银国际亚洲有限公司 CE AET863
中信里昂证券有限公司 CE AAB893
工银国际证券有限公司 CE ARO299
浦银国际融资有限公司 CE BFZ375
Joint Lead Managers (9)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
海通国际证券有限公司 CE AAF806
中银国际亚洲有限公司 CE AET863
中信里昂证券有限公司 CE AAB893
工银国际证券有限公司 CE ARO299
浦银国际融资有限公司 CE BFZ375
金联证券有限公司 CE BHH779
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 77,454,800 HKD | — | 1.91% | — | 6 months | 2021-01-08 |
| 2 | Anlan Funds | 38,722,800 HKD | — | 0.96% | — | 6 months | 2021-01-08 |
| 3 | AVICT Global Holdings Limited | 232,382,800 HKD | — | 5.74% | — | 6 months | 2021-01-08 |
| 4 | OrbiMed Funds | 387,310,800 HKD | — | 9.56% | — | 6 months | 2021-01-08 |
| 5 | 欧万达基金管理有限公司 | 116,186,800 HKD | — | 2.87% | — | 6 months | 2021-01-08 |
Directors & Management
| Chairman | 李鋰 |
|---|---|
| Company Secretary | 錢風奇;陳詩婷 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李鋰(60.12%) |
|---|
IPO Timeline
